PURPOSE: Evaluation of dose escalated salvage radiotherapy (SRT) in patients after radical prostatectomy (RP) who had never received antihormonal therapy.
To investigate prognostic factors of the outcome of SRT and to analyze which patient subsets benefit most from dose escalation.
MATERIALS AND METHODS: Between 2002 and 2008, 76 patients were treated in three different dose-groups: an earlier cohort treated with 66 Gy irrespective of pre-RT-characteristics and two later cohorts treated with 70 Gy or 75 Gy depending on pre-RT-characteristics. Biochemical-relapse-free-survival (bRFS), clinical-relapse-free-survival (cRFS) and late toxicity were evaluated.
RESULTS: Four-year bRFS and cRFS were 62.5% and 85%. Gleason score < 8, positive surgical resection margin (PSRM) and low PSA (≤ 0.5 ng/ml) before SRT resulted in higher bRFS. Analysis of the whole group showed no clear dose-outcome relationship. Patients with PSRM, however, had improved bRFS when escalating >66 Gy. While > 70 Gy did not improve the overall results, 4-year bRFS for patients with manifest local recurrence in the high-dose group was still comparable to those without manifest local recurrences. No grade 4 and minimal grade 3 gastrointestinal and urinary toxicity were observed.
CONCLUSIONS: Dose-escalated SRT achieves high biochemical control. The data strongly support the application of at least 70 Gy rather than 66 Gy. They do not prove positive effects of doses >70 Gy but do not disprove them as these doses were only applied to an unfavorable patients selection.
Written by:
Shelan M, Abo-Madyan Y, Welzel G, Bolenz C, Kosakowski J, Behnam N, Wenz F, Lohr F. Are you the author?
Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Reference: Radiat Oncol. 2013 Nov 27;8:276.
doi: 10.1186/1748-717X-8-276
PubMed Abstract
PMID: 24279376
UroToday.com Prostate Cancer Section
